KRAS and neoplasm: Tumor mutation hotspots associated with clinical resistance to anti-EGFR mAbs like KRAS exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), exon 4 (codons 117 and 146) and NRAS exon 2 (codons 12 and 13), exon 3 (codons 59 and 61) and exon 4 (codons 117 and 146) are now well identified and are systematically assessed prior to anti-EGFR mAbs prescription1–5.